Viatris yanks one batch of diabetes med Semglee because of missing label risks

Patients rely on drug labels to ensure they're using their medications correctly. When those labels are MIA, recalls are sure to follow.

Such is the case with Viatris' Mylan, which said Wednesday it was pulling one batch of non-interchangeable Semglee, also known as insulin glargine injection. The generics maker cited the risk of the label being missing on some prefilled pens contained inside labeled cartons of the drug.